|
📚 OPRD Special Issue on Nitrosamines -Pub
|
|
13
|
2367
|
January 23, 2024
|
|
N-nitroso Torasemide Impurity formation and control
|
|
23
|
1844
|
January 5, 2024
|
|
Formation of N-Nitrosamines by Reaction of Secondary Dialkylamines with Trace Levels of Nitrite in Aqueous Solution: An Automated Experimental and Kinetic Modeling Study Using Di-n-butylamine
|
|
2
|
1093
|
December 30, 2023
|
|
N-nitrosamines considerations for Inhalation products
|
|
10
|
1017
|
December 24, 2023
|
|
N- NITROSO DESMETHYL LOPERAMIDE is it possible?
|
|
4
|
535
|
December 18, 2023
|
|
Redefining Nitrosamine Risks: A Fresh Perspective on Pharmaceuticals -Pub
|
|
16
|
2313
|
December 17, 2023
|
|
New data released into Lhasa Carcinogenicity Database
|
|
1
|
970
|
November 17, 2023
|
|
Why do some mutagenic N-nitrosamines not require metabolic activation?
|
|
0
|
398
|
November 15, 2023
|
|
Review of NDSRIs in Pharmaceutical Drugs -Pub
|
|
1
|
855
|
November 13, 2023
|
|
Does atmospheric NO2 influence the formation of NDMA in metformin?
|
|
2
|
608
|
November 3, 2023
|
|
Not all Nitro structures are Nitrosamines!
|
|
1
|
840
|
November 2, 2023
|
|
Developing Structure-Activity Relationships for N-Nitrosamine Activity
|
|
7
|
650
|
October 13, 2023
|
|
Nitrosamines in Biologics
|
|
1
|
652
|
September 18, 2023
|
|
Nitrite Detection at Picogram Level, is it possible?
|
|
4
|
1052
|
September 14, 2023
|
|
Identifying the Risk of Formation of Nitrosamines and Other Potentially Mutagenic Impurities during API Manufacture Using In Silico Risk Assessment -Pub
|
|
0
|
1155
|
June 6, 2023
|
|
A deep dive into historical Ames study data for N-nitrosamine compounds -Pub
|
|
0
|
448
|
September 8, 2023
|
|
A nitrosamine twist
|
|
0
|
472
|
August 24, 2023
|
|
Strategies for Assessing Acceptable Intakes for Novel N-Nitrosamines Derived from Active Pharmaceutical Ingredients
|
|
4
|
668
|
August 23, 2023
|
|
Approaches and Considerations for the Investigation and Synthesis of N‑Nitrosamine Drug Substance-Related Impurities (NDSRIs)
|
|
0
|
694
|
August 23, 2023
|
|
Maximizing use of existing carcinogenicity data to support AI levels -Pub
|
|
0
|
374
|
July 31, 2023
|
|
Genotoxicity Assessment using HepaRG Models
|
|
2
|
471
|
July 28, 2023
|
|
Forced degradation: predicting nitrosamine formation
|
|
8
|
1733
|
July 20, 2023
|
|
Approaches and Considerations for the Investigation and Synthesis of N-Nitrosamine Drug Substance-Related Impurities (NDSRIs)
|
|
1
|
855
|
May 31, 2023
|
|
Impact of N‑nitrosamines presence and ARB recall on ARB utilization – results from IQVIA™ Disease Analyzer
|
|
1
|
429
|
May 2, 2023
|
|
Nuevas inspecciones en busca de Nitrosaminas y Genotóxicos en API no evaluados
|
|
1
|
749
|
May 1, 2023
|
|
Drawing a line: Where might the cohort of concern end?
|
|
5
|
1000
|
April 18, 2023
|
|
N-Nitrosamines and their precursors in wastewater effluents from selected industries in Spain -Pub
|
|
0
|
319
|
March 29, 2023
|
|
Computational Prediction of Metabolic α-Carbon Hydroxylation Potential of N-Nitrosamines: Overcoming Data Limitations for Carcinogenicity Assessment
|
|
5
|
887
|
March 23, 2023
|
|
The Landscape of Small and Drug Substance Related Nitrosamines in Pharmaceuticals
|
|
10
|
1791
|
March 8, 2023
|
|
U̶p̶c̶o̶m̶i̶n̶g̶ Nitrosamine Special Issue of JPS
|
|
3
|
1963
|
March 7, 2023
|